Results 221 to 230 of about 196,807 (276)

Multimodal treatment of radiation-associated laryngeal angiosarcoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Pan Y, Liu X, Nie X, Wang S, Zeng W.
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. [PDF]

Front Immunol
Wu C, Li S, Hou X.
europepmc   +1 more source

Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

Cancer Science, EarlyView.
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Akito Hata, Akira Kisohara, Shoichi Kuyama, Masafumi Yamaguchi, Asako Miwa, Shunichiro Iwasawa, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. [PDF]

Sci Rep
Sadetsky N, Prince P, Latimer H, Advani P, Smith-Gaziani D, Kaufman PA, Natanzon Y, Taylor A, Nguyen L, Freemantle N.   +9 more
europepmc   +1 more source

Targeting SPP1‐CD44‐Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis

Cancer Science, EarlyView.
SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara, Shu Shimada, Yoshimitsu Akiyama, Megumi Hatano, Yusuke Chino, Suguru Miyazawa, Hanako Tamura, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Shuichi Watanabe, Eriko Katsuta, Keiichi Akahoshi, Kenichi Ohashi, Minoru Tanabe, Daisuke Ban, Shinji Tanaka   +16 more
wiley   +1 more source

Modified Wen Luo Tong Alleviated Chemotherapy-Induced Peripheral Neuropathy via Regulating the CX3CL1/CX3CR1 Axis Through Inhibiting NF-κB and STAT3 Pathways. [PDF]

Integr Cancer Ther
Wu F, Zhang J, Wang H, Luo H, Lyu H, Zhang Y, Ling G, Li Y, Li J, Wang W, Wang Q, Lu L.   +11 more
europepmc   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Efficacy and safety of perioperative immunotherapy for locally advanced thymic squamous cell carcinoma: a retrospective pilot study. [PDF]

Front Surg
Li D, Zou Y.
europepmc   +1 more source

Hippo Pathway Drives Durable Non‐Cell‐Autonomous Ferroptosis Resistance in Lung Cancer

Cancer Science, EarlyView.
YAP/TAZ, key effectors in lung cancer progression, paradoxically sensitize tumor cells to ferroptosis. This study reveals that YAP/TAZ‐low cells confer non‐cell‐autonomous, GCH1‐mediated durable ferroptosis resistance to neighboring YAP/TAZ‐high cells via a soluble factor, highlighting a Hippo pathway‐linked mechanism of tumor adaptation and survival ...
Mohamed Fathi Saleh, Akihiro Nita, Yudai Ohta, Aya Kobayashi, Hao Li, Yasuhisa Sakamoto, Toshiro Moroishi   +6 more
wiley   +1 more source